作者

David Mulder

高级律师

Read More

Christian Dekoninck

合伙人

Read More

Adrian Toutoungi

合伙人

Read More

Dr. Anja Lunze, LL.M.

合伙人

Read More

Dr. Angela Knierim

授薪合伙人

Read More
作者

David Mulder

高级律师

Read More

Christian Dekoninck

合伙人

Read More

Adrian Toutoungi

合伙人

Read More

Dr. Anja Lunze, LL.M.

合伙人

Read More

Dr. Angela Knierim

授薪合伙人

Read More

2020年11月23日

Pharmaceutical patent law – 2 / 2 观点

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

  • Quick read

Which extraordinary regulations have been put in place for speeding up clinical trials in emergency situations like the current coronavirus pandemic? And how is early access to new medicines warranted under such circumstance?

The second part of the two-part series ‘Pharmaceutical Patent Law in Times of Crisis: A Comparative Study’, written for the European Intellectual Property Review by our international team, addresses these questions and more on both a broad, European level and from the perspective of six national jurisdictions.
 

Read the article here

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

UPC

It is time to think about UPC opt-out again: how it is achieved and its strategic implications

Part 2

2022年1月17日
In-depth analysis

作者

点击此处了解更多
UPC

It is time to think about UPC opt-out again: what opt-out does

Part 1

2022年1月17日
In-depth analysis

作者

点击此处了解更多
专利与创新

Taylor Wessing announces a major Unified Patent Court publishing project

2021年11月22日
Quick read

作者

点击此处了解更多